Immunocore (NASDAQ:IMCR) plc, trading as NASDAQ:IMCR, is a leading biotechnology company pioneering T cell receptor (TCR) based immunotherapies designed to direct the body’s immune system against cancer and other serious diseases. Founded in 2008 as a spin-out from the UK’s Medical Research Council, Immunocore has built its proprietary ImmTAC (immune mobilising monoclonal TCRs Against Cancer) platform to recognize intracellular targets inaccessible to conventional antibody therapies. The company’s mission is to extend the principles of immuno-oncology across a range of tumor types and antigen classes, enabling novel therapeutic approaches for patients with high unmet medical need.
Immunocore’s flagship product, tebentafusp (KIMMTRAK), received regulatory approval in multiple markets, including the United States, European Union and United Kingdom, for the treatment of HLA-A*02:01 positive adult patients with unresectable or metastatic uveal melanoma. Beyond its approved indication, the candidate is under evaluation in earlier lines of uveal melanoma as well as other solid tumors in combination with established immunotherapies. The company’s research pipeline also features next-generation ImmTAC molecules targeting antigens such as PRAME, MAGE-A4 and glypican-3, advancing through various stages of clinical development in melanoma, soft tissue sarcoma, prostate cancer and other solid tumors.
Headquartered in Oxford, United Kingdom, Immunocore maintains research and development centers in Seattle and Philadelphia, as well as corporate offices in New York. This global footprint supports collaborative partnerships with leading pharmaceutical companies and academic institutions, driving translational research and expansion into new therapeutic areas. The company’s cross-functional teams of immunologists, structural biologists and clinical development experts are focused on leveraging the ImmTAC platform to address a broad spectrum of indications with significant unmet needs.
Under the leadership of Chief Executive Officer Bahija Jallal, Immunocore has advanced from a pioneering platform developer to a commercial-stage oncology company. Jallal, who joined the company in 2022, brings more than two decades of experience in biotechnology and health care, having held senior roles at Pfizer, MedImmune and Sanofi. With a strategic emphasis on pipeline diversification, global regulatory engagement and manufacturing scale-up, the company is poised to extend the clinical impact of TCR-based immunotherapies and explore novel disease areas beyond oncology.
